Evaluating change in disease activity needed to reflect meaningful improvement in quality of life for clinical trials in cutaneous lupus erythematosus

• Published in: Journal of the American Academy of Dermatology 2021-06, Vol.84 (6), p.1562-1567
• Main Authors: Chakka, Srita, Krain, Rebecca L., Ahmed, Sarah, Concha, Josef Symon S., Feng, Rui, Merrill, Joan T., Werth, Victoria P.
• Format: Article
• Language: English
• Subjects: autoimmune skin disease; clinical trials; cutaneous lupus erythematosus; efficacy measures; patient-reported outcomes; quality of life
• ISSN: 0190-9622; 1097-6787
• DOI: 10.1016/j.jaad.2020.07.047

Outcome measures of clinical trials in cutaneous lupus erythematosus (CLE) should reflect clinically meaningful improvement in disease activity, as measured by the Cutaneous Lupus Disease Area and Severity Index activity score (CLASI-A). We aimed to define the degree of improvement in disease activity meaningful to a patient's quality of life. The change in the CLASI-A in 126 patients needed to predict meaningful change in QoL, as defined by the Emotions and Symptoms subscales of the Skindex-29, was evaluated by linear regression models. In patients with an initial CLASI-A of ≥8, a 42.1% or ≥7-point and a 31.0% or ≥5-point decrease in CLASI-A predicts meaningful improvement in the Emotions and the Symptoms subscales, respectively. This is a retrospective study of prospectively collected data at a single site. A CLASI-A score of ≥8 for trial entry allows for inclusion of patients with milder disease where CLASI-A improvement by ≥50% is clinically significant and meaningful.